When there was a bit debate about whether the Food and Drug Administration should withdraw Avastin's accelerated approval in breast cancer, I and others observed that the real complain should be that FDA did not grant accelerated approval of another Roche drug, known as T-DM1.
When there was a bit debate about whether the Food and Drug Administration should withdraw Avastin's accelerated approval in breast cancer, I and others observed that the real complain should be that FDA did not grant accelerated approval of another Roche drug, known as T-DM1.